All In MedTech

FDA Clearance Tracker · P990027-S012

BAUSCH & LOMB TECHNOLAS 217Z ZYOPTIX SYSTEM FOR PERSONALIZED VISION CORRECTION

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 26, 2009 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 26, 2009

Approved

Time to decision

42 days

Received May 15, 2009. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P990027-S012
Device name
BAUSCH & LOMB TECHNOLAS 217Z ZYOPTIX SYSTEM FOR PERSONALIZED VISION CORRECTION
Applicant location
MüNchen
Received
May 15, 2009
Decided
Jun 26, 2009
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P990027

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code LZS

FDA's approval statement

As written in FDA's record.

APPROVAL FOR A MANUFACTURING SITE CHANGE LOCATED AT TECHNOLAS PERFECTVISION GMBH, MUNICH, GERMANY.

Source documents

Other decisions for Technolas Perfect Vision GmbH

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

4 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.